21. LB0006 SUBCUTANEOUS SECUKINUMAB 300MG AND 150MG PROVIDES SUSTAINED INHIBITION OF RADIOGRAPHIC PROGRESSION IN PSORIATIC ARTHRITIS OVER 2 YEARS: RESULTS FROM THE PHASE 3 FUTURE-5 TRIAL. (June 2019) Authors: Mease, Philip J.; B.M. Landewé, Robert; Rahman, Proton; Tahir, Hasan; Singhal, Atul; Boettcher, Elke; Navarra, Sandra; Readie, Aimee; Mpofu, Shephard; Maria Delicha, Eumorphia; Pricop, Luminita; van der Heijde, Désirée Journal: Annals of the rheumatic diseases Issue: Volume 78(2019)Supplement 2 Page Start: 262 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
22. Long-term efficacy and safety of secukinumab in patients with psoriatic arthritis: 5-year (end-of-study) results from the phase 3 FUTURE 2 study. (April 2020) Authors: McInnes, Iain B; Mease, Philip J; Kivitz, Alan J; Nash, Peter; Rahman, Proton; Rech, Jürgen; Conaghan, Philip G; Kirkham, Bruce; Navarra, Sandra; Belsare, Ashwini D; Delicha, Eumoprhia M; Pricop, Luminita Journal: Lancet Issue: Volume 2:Number 4(2020) Page Start: e227 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
23. Management of non‐renal manifestations of systemic lupus erythematosus: A systematic literature review for the APLAR consensus statements. (2nd August 2022) Authors: Kasitanon, Nuntana; Hamijoyo, Laniyati; Li, Meng Tao; Oku, Kenji; Navarra, Sandra; Tanaka, Yoshiya; Mok, Chi Chiu Journal: International journal of rheumatic diseases Issue: Volume 25:Number 11(2022) Page Start: 1220 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
24. Mortality and adverse events of special interest with intravenous belimumab for adults with active, autoantibody-positive systemic lupus erythematosus (BASE): a multicentre, double-blind, randomised, placebo-controlled, phase 4 trial. (February 2021) Authors: Sheikh, Saira Z; Scheinberg, Morton A; Wei, James Cheng-Chung; Tegzova, Dana; Stohl, William; de Toledo, Ricardo Acayaba; Mucenic, Tamara; Banfi, Mauricio R Abello; Maksimowicz-McKinnon, Kathleen; Abud-Mendoza, Carlos; Navarra, Sandra; Garcia, Mercedes; Garcia-De La Torre, Ignacio; Ros, Josep Ord... Journal: Lancet Issue: Volume 3:Number 2(2021) Page Start: e122 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
25. OP0246 ATTAINMENT OF THE LUPUS LOW DISEASE ACTIVITY STATE IS ASSOCIATED WITH PROTECTION FROM DAMAGE ACCRUAL IN PATIENTS WITH ACTIVE DISEASE AT BASELINE. (June 2019) Authors: Golder, Vera; Morand, Eric F.; Kandane-Rathnayake, Rangi; Huq, Molla; Nim, Hieu; Louthrenoo, Worawit; Luo, Shue Fen; Wu, Yeong-Jian; Lateef, Aisha; Sockalingam, Sargunan; Navarra, Sandra; Zamora, Leonid; Hamijoyo, Laniyati; Katsumata, Yasuhiro; Harigai, Masayoshi; Chan, Madelynn; O'neill, Sean; G... Journal: Annals of the rheumatic diseases Issue: Volume 78(2019)Supplement 2 Page Start: 203 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
26. OP0330 #X00A0; COMPARISON OF THE EFFECTS OF DORIS REMISSION AND LUPUS LOW DISEASE ACTIVITY STATE (LLDAS) ON DISEASE OUTCOMES IN A MULTINATIONAL PROSPECTIVE STUDY. (June 2019) Authors: Golder, Vera; Morand, Eric F.; Kandane-Rathnayake, Rangi; Huq, Molla; Louthrenoo, Worawit; Luo, Shue Fen; Wu, Yeong-Jian; Lateef, Aisha; Sockalingam, Sargunan; Navarra, Sandra; Zamora, Leonid; Hamijoyo, Laniyati; Katsumata, Yasuhiro; Harigai, Masayoshi; Chan, Madelynn; O'neill, Sean; Goldblatt, F... Journal: Annals of the rheumatic diseases Issue: Volume 78(2019)Supplement 2 Page Start: 248 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
27. P250 Effect of secukinumab on radiographic progression through 2 years in patients with active PsA: end-of-study results from a Phase 3 study. (20th April 2020) Authors: Tahir, Hasan; Mease, Philip; Landewé, Robert; Rahman, Proton; Singhal, Atul; Böttcher, Elke; Navarra, Sandra; Readie, Aimee; Mpofu, Shephard; Delicha, Eumorphia-Maria; Pricop, Luminita; van der Heijde, Désirée Journal: Rheumatology Issue: Volume 59(2020)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
28. P258 Secukinumab Improves Physical Function and Inhibits Structural Damage in Psoriatic Arthritis PsA Patients With Sustained Remission or Low Disease Activity: Results From a Phase 3 Study. (23rd April 2022) Authors: Coates, Laura C; Mease, Philip J; Gladman, Dafna D; Navarra, Sandra; Bao, Weibin; Gaillez, Corine Journal: Rheumatology Issue: Volume 61(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
29. Prevention of infective complications in systemic lupus erythematosus: A systematic literature review for the APLAR consensus statements. (17th May 2021) Authors: Oku, Kenji; Hamijoyo, Laniyati; Kasitanon, Nuntana; Li, Meng Tao; Navarra, Sandra; Morand, Eric; Tanaka, Yoshiya; Mok, Chi Chiu Journal: International journal of rheumatic diseases Issue: Volume 24:Number 7(2021) Page Start: 880 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
30. Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study. Issue 6 (17th March 2018) Authors: Mease, Philip; van der Heijde, Désirée; Landewé, Robert; Mpofu, Shephard; Rahman, Proton; Tahir, Hasan; Singhal, Atul; Boettcher, Elke; Navarra, Sandra; Meiser, Karin; Readie, Aimee; Pricop, Luminita; Abrams, Ken Journal: Annals of the rheumatic diseases Issue: Volume 77:Issue 6(2018) Page Start: 890 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗